DDInter1594 DDInter172
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Rilonacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Rilonacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dactinomycin
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rilonacept {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Rilonacept {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Rilonacept may lead to a major life threatening interaction when taken with Fingolimod
Rilonacept may lead to a major life threatening interaction when taken with Leflunomide